Sara Nik
Stock Analyst at H.C. Wainwright
(0.07)
# 4,857
Out of 5,133 analysts
69
Total ratings
15.5%
Success rate
-26.5%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Sara Nik
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRIS Curis | Reiterated: Buy | $43 → $6 | $0.445 | +1,248.31% | 11 | Nov 13, 2026 | |
| KTTA Pasithea Therapeutics | Reiterated: Buy | $3 → $4 | $0.522 | +666.28% | 15 | Nov 13, 2026 | |
| TVRD Tvardi Therapeutics | Reiterated: Buy | $9 | $1.18 | +662.71% | 6 | Nov 13, 2026 | |
| EIKN Eikon Therapeutics | Reiterated: Buy | $23 | $5.98 | +284.62% | 3 | Nov 12, 2026 | |
| STO: CANTA Cantargia AB (publ) | Reiterated: Buy | kr 12.00 | kr 1.39 | +764.55% | 13 | Nov 9, 2026 | |
| MBRX Moleculin Biotech | Reiterated: Buy | $60 | $7.87 | +662.39% | 20 | Sep 29, 2026 | |
| KAPA Kairos Pharma | Reiterated: Buy | $12 | $0.4536 | n/a | 1 | Aug 13, 2025 |
Curis
Nov 13, 2026
Reiterated: Buy
Price Target: $43 → $6
Current: $0.445
Upside: +1,248.31%
Pasithea Therapeutics
Nov 13, 2026
Reiterated: Buy
Price Target: $3 → $4
Current: $0.522
Upside: +666.28%
Tvardi Therapeutics
Nov 13, 2026
Reiterated: Buy
Price Target: $9
Current: $1.18
Upside: +662.71%
Eikon Therapeutics
Nov 12, 2026
Reiterated: Buy
Price Target: $23
Current: $5.98
Upside: +284.62%
Cantargia AB (publ)
Nov 9, 2026
Reiterated: Buy
Price Target: kr 12.00
Current: kr 1.39
Upside: +764.55%
Moleculin Biotech
Sep 29, 2026
Reiterated: Buy
Price Target: $60
Current: $7.87
Upside: +662.39%
Kairos Pharma
Aug 13, 2025
Reiterated: Buy
Price Target: $12
Current: $0.4536
Upside: n/a